KDR and sarcoma: A retrospective analysis of patients with relapsed, metastatic, or unresectable sarcomas treated with nivolumab and the multi-RTK inhibitor pazopanib (VEGFR, PDGFR, and KIT) further showed a CBR in two out of the three included osteosarcoma patients, of which one patient had a PR [65].